What is NDC 54092-471?

54092-471 is the product NDC for Mydayis, Dextroamphetamine sulfate 6.25 mg/1 + 3 more ingredients capsule, extended release, listed with the FDA by Takeda Pharmaceuticals America, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Mydayis (DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, and AMPHETAMINE SULFATE).

What is the active ingredient?

Dextroamphetamine sulfate, Dextroamphetamine saccharate, Amphetamine aspartate monohydrate, Amphetamine sulfate.

Takeda Pharmaceuticals America, Inc., NDC labeler code 54092. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Mydayis?

3 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Mydayis NDC 54092-471 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)54092-471Labeler and product segments. Claims need a package NDC.

Product NDC at billing width54092-0471Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
54092-471-01	5409204710154092047101	100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (54092-471-01)Marketed from Jun 20, 2017

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Mydayis
Generic name (nonproprietary): dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate
Active ingredients: Dextroamphetamine sulfate — 6.25 mg/1Dextroamphetamine saccharate — 6.25 mg/1Amphetamine aspartate monohydrate — 6.25 mg/1Amphetamine sulfate — 6.25 mg/1
Dosage form: Capsule, Extended release
Route: Oral
Labeler: Takeda Pharmaceuticals America, Inc.NDC labeler code 54092
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 022063
Marketing start: Jun 20, 2017
Listing expires: Dec 31, 2027
DEA schedule: CII
Other FDA classes: Central Nervous System Stimulation (Physiologic effect)Central Nervous System Stimulation (Physiologic effect)Central Nervous System Stimulation (Physiologic effect)Central Nervous System Stimulation (Physiologic effect)
Identifiers: Product ID 54092-471_13a2ab7d-af84-4e46-a58f-9e9c17b5c0e5SPL ID 13a2ab7d-af84-4e46-a58f-9e9c17b5c0e5SPL set ID 141a7970-3f06-44ea-9ab7-aeece2c085fcRxCUI 1927610, 1927616, 1927617, 1927619, 1927630, 1927632, 1927637, 1927639UNII G83415V073, JJ768O327N, 6DPV8NK46S, O1ZPV620O4
Pharmacologic class: Central Nervous System Stimulant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N454092047101 followed by a unit qualifier and the quantity

Package 54092-0471-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 30, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

MYDAYIS is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older [see Clinical Studies (14) ] . MYDAYIS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older. ( 1 ) Limitations of Use : Pediatric patients 12 years and younger experienced higher plasma exposure than patients 13 years and older at the same dose and experienced higher rates of adverse reactions, mainly insomnia and decreased appetite. ( 8.4 ) Limitations of Use : Pediatric patients 12 years and younger experienced higher plasma exposure than patients 13 years and older at th…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 54092-471

What is NDC 54092-471?: 54092-471 is the product NDC for Mydayis, Dextroamphetamine sulfate 6.25 mg/1 + 3 more ingredients capsule, extended release, listed with the FDA by Takeda Pharmaceuticals America, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Mydayis (DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, and AMPHETAMINE SULFATE).
What is the active ingredient?: Dextroamphetamine sulfate, Dextroamphetamine saccharate, Amphetamine aspartate monohydrate, Amphetamine sulfate.
Who is the labeler?: Takeda Pharmaceuticals America, Inc., NDC labeler code 54092. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Mydayis?: 3 other product NDCs are listed under this name. See all Mydayis NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Mydayis NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Mydayisdextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate	Dextroamphetamine sulfate 3.125 mg/1 + 3 more ingredients	Capsule, Extended releaseOral	Takeda Pharmaceuticals America, Inc.	54092-468	54092-0468-01
Mydayisdextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate	Dextroamphetamine sulfate 9.375 mg/1 + 3 more ingredients	Capsule, Extended releaseOral	Takeda Pharmaceuticals America, Inc.	54092-474	54092-0474-01
Mydayisdextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate	Dextroamphetamine sulfate 12.5 mg/1 + 3 more ingredients	Capsule, Extended releaseOral	Takeda Pharmaceuticals America, Inc.	54092-477	54092-0477-01

Other NDCs under NDA 022063

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 022063
Product	Strength	Form · route	Labeler	Product NDC
Mydayisdextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate	Dextroamphetamine sulfate 3.125 mg/1 + 3 more ingredients	Capsule, Extended releaseOral	Takeda Pharmaceuticals America, Inc.	54092-468
Mydayisdextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate	Dextroamphetamine sulfate 9.375 mg/1 + 3 more ingredients	Capsule, Extended releaseOral	Takeda Pharmaceuticals America, Inc.	54092-474
Mydayisdextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate	Dextroamphetamine sulfate 12.5 mg/1 + 3 more ingredients	Capsule, Extended releaseOral	Takeda Pharmaceuticals America, Inc.	54092-477